Zyngenia is a privately held biotherapeutics company focused on the development of next-generation multi-specific antibody-based therapeutics.
Selexis co-founder and CEO Igor Fisch said that they are excited to support Zyngenia in the advancement of their lead Zybody products.
"It’s rare in today’s biotech environment to find a truly innovative antibody platform such as Zyngenia’s, where multiple disease targets can be addressed with a single protein therapy," Fisch said.
Zyngenia Research and Development head David Hilbert said that they recognise the importance of incorporating technologies in the development of the products and are pleased to be working with the experts at Selexis.
"Selexis’ technological focus, aggressive development strategies, and commercial flexibility were important factors in our choice of providers in this area," Hilbert said.